查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496027

全球肠道管理系统市场 - 2024 年至 2029 年预测

Global Bowel Management Systems Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 138 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

肠道管理系统市场预计将以 4.13% 的复合年增长率成长，从 2022 年的 811,927,000 美元增至 2029 年的 1,077,824,000 美元。

肠道管理系统是一种医疗应用，旨在帮助肠道控制受损的人，包括患有神经系统疾病的人，如神经源性肠功能障碍、脊髓相关损伤 它和多种类型的硬化症。由小工具、治疗和介入组成。这些系统的主要目的是观察、分析和监测排便情况，避免大便失禁和粪便滞留，并提高这些人的生活品质。这些系统包括饮食调整、药物治疗以及使用直肠栓剂、肠道静脉切开术和肠道灌注系统等治疗物品。

全球肠道管理系统产业包括用于解决肠道功能障碍和推进肠道管理的产品和解决方案的製造、分销和销售。促成这一市场扩张的变数主要是由于神经病变的主导地位、老年人口的增加、创新技术的进步、以患者为中心的方法以及医疗保健利用率的提高。

脊髓损伤、不同的硬化症和某些神经系统混乱等神经系统疾病可能导致肠道破损，从而推动对肠道管理安排的需求。科技进步为日常生活中监督肠道功能障碍的人们提供了更高的生存能力、安慰和舒适度。

市场驱动因素：

  • 肠道疾病发病率的上升和老年人口的增加预计将推动肠道管理系统市场的发展。

肠道管理系统透过帮助治疗大便失禁，帮助患者保持皮肤清洁、一尘不染。该装置是插入直肠的柔软导管，用于容纳和转移粪便。技术先进的肠道管理设备的可用性正在迅速增加，老年人口也在增加。

排便障碍相关疾病的增加是推动肠道管理系统市场成长的主要因素。此外，人们对这些设备可用性的认识不断提高，再加上满足许多未满足需求的新设备的推出，都有助于肠道管理系统市场的成长。

根据 2024 年 4 月的 AANP资料，大肠激躁症(IBS) 是一种慢性胃肠道疾病，影响着美国2,500 万至4,500 万人，并限制了他们的工作、上学和维持人际关係的能力。儘管影响了全球 5-10% 的人口，但 75% 的 IBS 患者可能未被诊断出来。寻求治疗的患者可能要等待长达四年的医疗保健。此外，新兴经济体有利的报销方案和肠道管理系统的技术进步正在推动市场成长。

大便不一致问题在成年人中更为常见，这加强了肠道管理系统市场。

随着年龄的增长，我们的认知功能会下降，注意力和控制血液循环的能力也会下降。排便不规律可能是一个新出现的问题，尤其是在人口老化的情况下，这推动了对肠道管理框架的需求。这些因素包括世界人口的老化、神经系统疾病、糖尿病和某些胃肠道疾病等持续存在的疾病，这些疾病可能导致肠道不规则。

此外，手术和治疗后可能会导致暂时或慢性肠道功能障碍，因此有效管理这些问题对个人来说极为重要。由于这些因素以及解决老龄化社会中日益增加的不便问题的需要，肠道管理系统市场预计将增长。许多成年人患有大便失禁，这刺激了对肠道管理框架的需求。

由于患有肠道相关疾病和併发症的人数不断增加，结肠造口袋的使用正在增加。推而广之，肠躁症等感染疾病在老化族群中较为常见。根据美国疾病管制与预防中心 2022 年 4 月的资料，IBD（包括克隆氏症和溃疡性大肠炎）影响着 1.3% 的美国成年人口（310 万成年人）。

预计北美地区将主导市场占有率。

由于严重感染疾病数量的增加、设备齐全的医疗保健系统和发达的医疗保健框架，预计北美地区在预测期内其行业份额将固有增加。此外，提高患者对各种肠道问题风险的认识也有望有助于该地区的市场扩张。

由于人口中肠癌和大肠癌等严重的数量不断增加，预计北美国家将在估计期间保持适度的市场规模并为市场扩张做出贡献。因此，肠道疾病影响老年人口的可能性正在扩大。

主要进展

  • 2024 年 2 月，康乐保推出了 Peristen(R) Light，这是一种经肛门冲洗装置，可为慢性便秘和大便失禁等肠道疾病患者提供支援。 Peristine Lite 是基于康乐保 20 年大容量灌注设备 Peristine Plus 的经验而开发的。
  • 2022 年 4 月 - Microbiotica 获得克隆氏症和结肠炎基金会的资助，用于开发治疗溃疡性大肠炎(UC) 的活细菌疗法 (LBT)。 MB310 是一种完全定义的 LBT，包含 10 种细菌菌株，其开发由克隆氏症和结肠炎基金会的 IBD Ventures 计划资助，用于 cGMP 製造和临床实验新药备案。
  • 2022 年 2 月 - 领先的造造口护理产品製造商康乐保在新加坡推出 SenSura(R) Mio。我们是东南亚第一个引进这种创新产品的国家。

我们的产品

  • Bioness 的用于治疗週边神经痛的医疗设备「StimRouter(R) Neuromodulation System」已获得 FDA核准和 CE 标誌。该系统在欧洲销售，医生可以将一个小型植入插入脚踝附近的胫神经来治疗大便失禁。该装置具有微创性，可轻鬆植入胫神经附近。
  • BARD DIGNISHEILD 粪便管理系统 - 全球领先的医疗设备公司 BD 提供 BARD DIGNISHEILD 粪便管理系统，可保护娇嫩组织免受洩漏、压力和摩擦造成的损坏。该系统包括导管组件、60cc 注射器、收集袋和润滑剂。其他产品包括除臭剂和管夹。
  • Rectobag - B. Braun Melsungen AG 是一家领先的医疗产品製造商，提供大便失禁和肠道管理领域的各种产品，包括 Rectobag 和直肠导管。 Rectobag 是一种封闭式系统，用于重复排便和诊断，长度为 10 厘米，配有锥形连接器、孔转移管和闭合夹。冲洗导管，也称为直肠导管，具有颜色编码的锥形配件、封闭的圆形尖端和两个横向定位的孔。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章肠道管理系统的全球市场：副产品

  • 介绍
  • 结肠造口袋
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 灌溉系统
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 神经调节剂
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章肠道管理系统的全球市场：依患者类型

  • 介绍
  • 成人
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 孩子
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章肠道管理系统的全球市场：依最终使用者分类

  • 介绍
  • 医院
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 门诊中心
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 居家护理
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第八章肠道管理系统的全球市场：按地区

  • 介绍
  • 北美洲
    • 副产品
    • 依患者类型
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 副产品
    • 依患者类型
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 副产品
    • 依患者类型
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 副产品
    • 依患者类型
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 副产品
    • 依患者类型
    • 按最终用户
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 有竞争力的仪表板

第十章 公司简介

  • Cogentix Medical
  • Hollister Incorporated
  • Mbh-International A/S
  • Mederi Therapeutics Inc
  • B. Braun Melsungen AG
  • Aquaflush Medical Limited
  • Consure
  • Wellspect health care
  • ConvaTec Group Plc.
  • ProSys International Ltd.
简介目录
Product Code: KSI061611766

The global bowel management systems market is projected to grow at a CAGR of 4.13% to reach US$1,077.824 million by 2029, from US$811.927 million in 2022.

The bowel management system consists of medical gadgets, procedures, and interventions meant to assist individuals with impaired bowel control including those with neurological clutter such as neurogenic bowel dysfunction, spinal cord-related injuries, and numerous types of sclerosis. The main goal of these systems is to observe, analyze, and monitor the movement of the bowel, avoid fecal incontinence or stoppage, and upgrade the quality of life for these people. These systems may incorporate dietary adjustments, medicines, and the utilization of therapeutic gadgets such as rectal suppositories, bowel purges, or bowel irrigation systems.

The worldwide bowel management systems industry incorporates the manufacturing, distribution, and sales of items and solutions outlined to address bowel dysfunction and progress bowel management. Variables contributing to this market expansion are majorly due to the predominance of neurological clutters, the growing senior-age populace, innovative technological progressions, a patient-centric approach, and rising healthcare use.

Neurological disorders, like spinal cord injuries, different sclerosis, and certain neurological clutters, can result in bowel brokenness, driving the request for bowel administration arrangements. Technological progressions offer moved forward viability, consolation, and comfort for people overseeing bowel dysfunction in their daily lives.

Market Drivers:

  • The increasing number of bowel diseases and the geriatric population are anticipated to boost the bowel management systems market.

The bowel management system helps patients maintain clean, uncontaminated skin by assisting with the treatment of fecal irregularity. The device is a soft catheter that is inserted into the rectum to contain and divert fecal waste. The surge in availability of technologically advanced devices for fecal management and the rise in the geriatric population.

The increase in fecal inconsistency-related disorders is the major factor that is driving the market for bowel management systems to grow. Furthermore, increased awareness of the availability of these devices, combined with the introduction of new devices that address many unserved needs contributes to the bowel management system market's growth.

According to the AANP data of April 2024, Irritable bowel syndrome (IBS), a chronic gastrointestinal condition affecting 25 to 45 million people in the US, can limit their ability to work, attend school, and maintain relationships. Despite affecting 5 to 10% of the global population, 75% of those with IBS may be undiagnosed. Patients seeking medical treatment may wait up to four years before seeing their healthcare provider. Furthermore, favorable reimbursement scenarios in developed economies, as well as technological advancements in bowel management systems, are driving the market growth.

The problem of fecal inconsistency is more prevalent among adults, which will bolster the bowel management systems market.

As individuals age, cognitive function declines, and alertness and control over bloody functions decrease, which is one reason geriatric individuals require assistance. Fecal irregularity, especially within the aging population, maybe a developing concern, driving the request for bowel administration frameworks. Components contributing to this involve the global maturing populace, persistent conditions such as neurological diseases, diabetes, and certain gastrointestinal illnesses, which can cause bowel irregularity.

Additionally, post-surgical and medical treatments can lead to temporary or chronic bowel dysfunction, making it crucial for individuals to manage these issues effectively. The bowel management systems market is expected to grow due to these factors and the need to address the growing issue of fecal inconsistency in the aging population. A large number of adults have fecal incontinence, which is fueling up the requirement for bowel management frameworks.

There is an increment within the utilization of colostomy bags as the number of people enduring illnesses and complications related to the bowel is expanding. In expansion, infections like irritable bowel disorder are more common among the aging population. According to the Centers for Disease Control and Prevention data of April 2022, IBD, including Crohn's disease and ulcerative colitis, affects 1.3% of the US adult population, including 3.1 million adults.

The North American region is predicted to dominate the market share.

The North American region is evaluated to increase essentially in industry share over the projected period owing to the increasing number of severe infections, well-positioned healthcare systems, and well-developed healthcare framework. Moreover, the increasing awareness among patients with respect to the hazards of different bowel issues is additionally anticipated to contribute to this region's market expansion.

Due to an increment in the number of severe illnesses like intestinal cancer and colorectal cancer among the populace, the North American countries are anticipated to hold moderate market size and contribute to its expansion over the estimated period. As a result, the chance of bowel diseases influencing the geriatric population is expanding.

Key Developments:

  • February 2024- Coloplast launched Peristeen(R) Light, a transanal irrigation device designed to help people with bowel disorders, including chronic constipation and fecal incontinence. Peristeen Light is based on 20 years of experience from Coloplast's high-volume gadget, Peristeen Plus. It is instinctive, easy to utilize, and collected in fair two steps with a delicate, adaptable catheter.
  • April 2022- Microbiotica received funding from the Crohn's & Colitis Foundation to develop a Live Bacterial Therapeutic (LBT) for ulcerative colitis (UC). The development of MB310, a fully defined LBT containing 10 bacterial species, is being funded by the Crohn's & Colitis Foundation's IBD Ventures program in preparation for cGMP manufacture and an investigational new drug application. Immune homeostasis can be restored and important UC disease pathology addressed by MB310.
  • February 2022- Coloplast, a leading manufacturer of stoma care products, launched SenSura(R) Mio in Singapore, the first Southeast Asian country to introduce this innovative product.

Company Product:

  • StimRouter(R) Neuromodulation System- Bioness, Inc. has received FDA approval and CE mark for its "StimRouter(R) Neuromodulation System," a medical device for treating peripheral nerve pain. The system, available in Europe, allows physicians to treat fecal or bowel incontinence by inserting a small implant into the tibial nerve near the ankle. The device is minimally invasive and easier to implant near the nerve Tibialis.
  • BARD DIGNISHEILD Stool Management System - BD, a leading global medical equipment company, offers the "BARD DIGNISHEILD Stool Management System" to protect delicate tissues from damage caused by leakage, pressure, or friction. The system incorporates a catheter tube assembly, a 60cc syringe, a collection bag, and a lubricating jelly. Additional products include an odor eliminator and a tube clamp. The system helps patients avoid exposure, tissue damage, and odor.
  • Rectobag - B. Braun Melsungen AG, a leading medical product manufacturer, offers a range of products under its Fecal Incontinence & Bowel Management segment, including a Rectobag and a Rectal Catheter. The Rectobag is a closed system used for repeated intestinal salvage and diagnostics, featuring a conical connector, bore transfer tube, and a 10 cm length with a closing clamp. The Irrigation Catheter, also known as a rectal catheter, has a color-coded cone fitting, a closed rounded tip, and two laterally positioned eyes.

Market Segmentation:

Global Bowel Management Systems Market is segmented and analyzed as below:

By Product

  • Colostomy Bags
  • Irrigation Systems
  • Nerve Modulation Devices
  • Others

By Patient Type

  • Adults
  • Paediatric

By End-User

  • Hospitals
  • Ambulatory Centers
  • Home Care

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL BOWEL MANAGEMENT SYSTEMS MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Colostomy Bags
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Irrigation Systems
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Nerve Modulation Devices
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL BOWEL MANAGEMENT SYSTEMS MARKET BY PATIENT TYPE

  • 6.1. Introduction
  • 6.2. Adults
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Paediatric
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness

7. GLOBAL BOWEL MANAGEMENT SYSTEMS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Ambulatory Centers
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Home Care
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL BOWEL MANAGEMENT SYSTEMS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Product
    • 8.2.2. By Patient Type
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Product
    • 8.3.2. By Patient Type
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Product
    • 8.4.2. By Patient Type
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. UK
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Spain
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Product
    • 8.5.2. By Patient Type
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. Israel
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Product
    • 8.6.2. By Patient Type
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. Japan
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. South Korea
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. India
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Thailand
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Taiwan
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Cogentix Medical
  • 10.2. Hollister Incorporated
  • 10.3. Mbh-International A/S
  • 10.4. Mederi Therapeutics Inc
  • 10.5. B. Braun Melsungen AG
  • 10.6. Aquaflush Medical Limited
  • 10.7. Consure
  • 10.8. Wellspect health care
  • 10.9. ConvaTec Group Plc.
  • 10.10. ProSys International Ltd.